Polyethylene glycol modified insulin-like polypeptide and application thereof
A technology of polyethylene glycol and insulin, which is applied to medical preparations with non-active ingredients, medical preparations containing active ingredients, peptides, etc., can solve the problems of short half-life of polypeptides, achieve long half-life, prevent or treat diabetes, Effects of treating or preventing diabetes
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 2
[0014] In vivo hypoglycemic experiment of polyethylene glycol-modified insulin-mimetic polypeptide
[0015] Kunming mice were fed with high-fat and high-sugar to a body weight of 18-22 g, half male and half female, fasted for 24 hours before the experiment, and intraperitoneally injected with streptozotocin (STZ) 50 mg / kg (1% citrate buffer). liquid solution preparation). One week later, blood glucose (BS) was measured by blood collection from the tail vein of the mice. If the BS was higher than 16mmol / L, the modeling was successful. After modeling, the mice were divided into 3 groups, 10 in each group. Diabetes model group (DM group): subcutaneous injection of the same amount of PBS buffer; control group (insulin): 20 μg / kg subcutaneous injection (dissolved in 0.1mol / LPBS buffer), twice a day for 15 consecutive days; sample group (polyethylene glycol-modified insulin-mimetic polypeptide): 1 mg / kg subcutaneous injection (dissolved in 0.1mol / LPBS buffer), once a day , for 15 ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 